Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab for adults with recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (MK-3475-629/KEYNOTE-629)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-11-19